reamberin and Hepatitis--Viral--Human

The study including 427 patients with acute and chronic viral hepatitis was designed to assess results of clinical and laboratory diagnostics of hepatic problems and the state of thiosulfide antioxidative system. It was shown that infusion of succinate-containing preparation reamberin (400 ml/day for 10 days) took less time to eliminate clinical manifestation of the disease (dispeptic and asthenovegetative syndromes) than conventional therapy. Simultaneously the levels of biochemical markers of hepatic cytolysis and cholestasis significantly decreased while serum antioxidative potential recovered. The normal size of the liver was achieved 3.4 times more frequently than in control. No side effects or adverse reactions other than listed in the instruction for use of reamberin occurred. The preparation had to be withdrawn only in one patient.

Topics: Acute Disease; Adolescent; Adult; Biomarkers; Chronic Disease; Cytoprotection; Female; Hepatitis, Viral, Human; Humans; Length of Stay; Male; Meglumine; Middle Aged; Succinates; Treatment Outcome; Young Adult